Trial Profile
A 12-Month Follow-Up Study to Protocol 24779 (A Double-blind, Prospective, Randomized, Placebo-controlled Study to Determine the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial Injections of G-CSF Mobilized Auto CD34+ Cells for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia [ACT34-CMI])
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs CLBS-14 (Primary)
- Indications Myocardial ischaemia
- Focus Adverse reactions
- Sponsors Baxter Healthcare Corporation; Caladrius Biosciences
- 05 Dec 2014 New trial record